WuXi To Go Private In $33bn CEO-Backed Deal
This article was originally published in Scrip
Executive Summary
Eight years after WuXi PharmaTech went public on the US stock market, the Shanghai-based clinical research organization (CRO) will become a private company again in a $3.3bn acquisition proposed by various private equity investors and WuXi executives, including chairman and CEO Ge Li.